Sarcomas

PRT2527-02

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies.

Open at Saint-Cloud since : 01/10/2023
Target : Adult
Phase : Phase I

Trial description

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib.

Url of the trial

Main investigator

CLEMENTINE SARKOZY

Médecin

Contact